Rhabdomyosarcoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
All patients with rhabdomyosarcoma require multimodality therapy with systemic [[chemotherapy]], in conjunction with either surgery, radiation therapy (RT), or both modalities to maximize local tumor control. | All patients with rhabdomyosarcoma require multimodality therapy with systemic [[chemotherapy]], in conjunction with either surgery, [[radiation therapy]] (RT), or both modalities to maximize local tumor control. | ||
===Chemotherapy=== | |||
Common agents include vincristine, cyclophosphamide, dactinomycin, adriamycin, ifosfamide, VP-16. | |||
==References== | ==References== | ||
Revision as of 18:46, 4 September 2015
|
Rhabdomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rhabdomyosarcoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Rhabdomyosarcoma medical therapy |
|
Risk calculators and risk factors for Rhabdomyosarcoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
All patients with rhabdomyosarcoma require multimodality therapy with systemic chemotherapy, in conjunction with either surgery, radiation therapy (RT), or both modalities to maximize local tumor control.
Chemotherapy
Common agents include vincristine, cyclophosphamide, dactinomycin, adriamycin, ifosfamide, VP-16.